<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173040</url>
  </required_header>
  <id_info>
    <org_study_id>Niubang Pill</org_study_id>
    <nct_id>NCT03173040</nct_id>
  </id_info>
  <brief_title>The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis</brief_title>
  <official_title>The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis: a Study Protocol for a Multicenter, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cui xuejun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Yueyang Integrated Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Seventh People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that
      results in the destruction of joints, connective tissues, muscle, tendons and fibrous tissue.
      Effective therapy to manage RA still does not exit at present. Jia Wei Niu Bang Zi pill
      (NBZP) consists of Chinese herbals which has been widely used in the treatment of RA patients
      in China for hundreds of years to relieve pain and prevent the affected joints pejorative.
      However, there is no systematic trials to prove the effect of NBZP for management of RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled clinical trials will be conducted
      to determine whether the NBZP could make an effect of pain relief and joints protection. 120
      patients suffering from active RA will be enrolled and treated with NBZP or placebo for 3
      months. The primary outcome measures are the rate of American College of Rheumatology (ACR)
      50, changes of the Disease Activity Score (DAS) 28 from the baseline to 3 months and the van
      der Heijde modified Sharp score would be measured from the baseline to 12 months. The second
      outcome measures are the change rate of ACR20, ACR70, Health Assessment Questionnaire -
      Disability Index, change score of Patient Assessment of Arthritis Pain, Patient Global
      Assessment of Arthritis, Patient Global Assessment of Arthritis and the Athens Insomnia Scale
      (AIS) from the baseline to 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months'
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ACR (American College of Rheumatology) 50</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of the van der Heijde modified Sharp score</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of The Disease Activity Score (DAS) 28</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR (American College of Rheumatology) 50</measure>
    <time_frame>at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR (American College of Rheumatology) 50</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR (American College of Rheumatology) 50</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR (American College of Rheumatology) 50</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ACR (American College of Rheumatology) 50</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Health Assessment Questionnaire - Disability Index</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Assessment of Arthritis Pain</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of Patient Global Assessment of Arthritis</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of 36-item Short-Form Health Survey Questionnaire</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of MOS Sleep Scale</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of MOS Sleep Scale</measure>
    <time_frame>from baseline to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of MOS Sleep Scale</measure>
    <time_frame>from baseline to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of MOS Sleep Scale</measure>
    <time_frame>from baseline to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of MOS Sleep Scale</measure>
    <time_frame>from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change score of MOS Sleep Scale</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR20</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ACR70</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Niu Bang Zi Pill</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>NiuBangZi pill group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placeo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NiuBangZi pill or NiuBangZi pill placebo</intervention_name>
    <description>For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.</description>
    <arm_group_label>NiuBangZi pill group</arm_group_label>
    <arm_group_label>Placeo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with rheumatoid arthritis (score more then 5 of ACR (American College Of
             Rheumatology) /EULAR (European League Against Rheumatism), 2009 )

          -  moderate-to-severe disease activity (Disease Activity Score for 28-joint counts
             (DAS28) of more than 3.2

          -  an onset of symptoms within 12 months before enrollment, no prior exposure to more
             than 10mg oral glucocorticoids or biologic agents

          -  paid employment or unpaid but measurable work (e.g. caring for a family and home)

        Exclusion Criteria:

          -  combined with other disease such as adjuvant arthritis, lupus arthritis,
             osteoarthritis and et al.

          -  abnormal liver and my kidney function

          -  pregnancy or have a plan of pregnancy,breast feeding women

          -  severe chronic or acute disease interfering with therapy attendance

          -  alcohol or substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongjun Wang, Doctor</last_name>
    <phone>86-18917763018</phone>
    <email>yjwang8888@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qianqian Liang, Doctor</last_name>
    <phone>86-021-64875390</phone>
  </overall_contact_backup>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>June 24, 2017</last_update_submitted>
  <last_update_submitted_qc>June 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Cui xuejun</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Traditional Chinese medicine</keyword>
  <keyword>Niu Bang Zi pill</keyword>
  <keyword>methotrexate</keyword>
  <keyword>active rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

